Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Rosner S, Reuss JE, Zahurak M, Zhang J, et al. Clin Cancer Res 2023;29:705-710.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rosner S, Reuss JE, Zahurak M, Zhang J, et al. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 2023;29:705-710.
PMID: 36794455